# Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

> **NCT00003516** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 16 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003516
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-03-27
- **Primary completion:** 2004-03-18
- **Final completion:** 2004-03-18
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003516, "Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00003516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*